Mycoplasma in Poultry: Causes, Clinical Signs in Chicken Poop, and Control Strategies

1. Introduction

Avian mycoplasmosis represents a group of economically significant infectious diseases affecting poultry worldwide, primarily caused by pathogenic species within the genus Mycoplasma [1]. The most clinically relevant species in commercial poultry are Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), though other species such as Mycoplasma meleagridis and Mycoplasma iowae also cause disease in turkeys [2, 3]. These organisms are classified within the class Mollicutes, characterized by the absence of a cell wall, a reduced genome size, and a dependence on host-derived nutrients for survival [1]. The lack of a cell wall renders these bacteria intrinsically resistant to beta-lactam antimicrobials and confers a unique set of vulnerabilities and diagnostic challenges [4, 5]. Infections with MG and MS lead to chronic respiratory disease, synovitis, airsacculitis, and egg production losses, resulting in substantial economic burdens for the poultry industry [6, 3]. This article provides a detailed examination of the causes of avian mycoplasmosis, the clinical manifestations with a specific focus on fecal abnormalities, and a comprehensive overview of current and emerging control strategies.

2. Etiology and Pathogen Biology

2.1. The Genus Mycoplasma

Mycoplasmas are the smallest self-replicating organisms, with genomes ranging from approximately 0.58 to 1.38 Mb [1]. Their minimalistic genome encodes a reduced metabolic repertoire, necessitating a parasitic or saprophytic lifestyle [1]. The cell membrane is composed of a lipid bilayer with embedded proteins, including variable surface lipoproteins that play critical roles in antigenic variation and immune evasion [6]. Comparative genomic analyses have revealed that avian mycoplasmas possess a core set of genes essential for host colonization and basic metabolism, along with species-specific genes associated with virulence and host tropism [1].

2.2. Primary Pathogenic Species

Mycoplasma gallisepticum is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys [2, 3]. MG is a highly contagious pathogen that colonizes the respiratory epithelium, leading to inflammation, ciliostasis, and secondary bacterial infections [6]. Mycoplasma synoviae is the causative agent of infectious synovitis, characterized by inflammation of the synovial membranes of joints and tendon sheaths, and can also cause respiratory disease and eggshell apex abnormalities (EAA) [7, 8, 9]. Both MG and MS can be transmitted horizontally through direct contact, airborne droplets, and contaminated fomites, as well as vertically through the egg [10, 11]. Mycoplasma meleagridis primarily affects turkeys, causing airsacculitis and leg deformities, while Mycoplasma iowae is associated with reduced hatchability and embryo mortality [12, 3].

2.3. Pathogenesis and Host Interaction

The pathogenic mechanisms of avian mycoplasmas involve adherence to host epithelial cells, evasion of the host immune response through antigenic variation, and the induction of pro-inflammatory cytokines [6, 13]. MG utilizes adhesins such as GapA and CrmA to bind to tracheal epithelial cells, leading to ciliary stasis and loss of mucociliary clearance [6]. The organism also activates the MAPK pathway and induces autophagy in host cells, contributing to tissue damage and inflammation [14, 13]. MS employs glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a moonlighting protein to facilitate colonization of the lower respiratory tract [15, 16]. The organism also triggers inflammatory and apoptotic responses in avian macrophages via the PIK3CA pathway [17]. Co-infections with other pathogens, such as Pasteurella multocida, Avibacterium paragallinarum, or Cryptosporidium baileyi, can exacerbate disease severity [2, 7, 18].

3. Clinical Signs and Fecal Abnormalities

3.1. Respiratory and Systemic Signs

Clinical signs of MG infection in chickens include rales, coughing, sneezing, nasal discharge, and conjunctivitis [6, 3]. In turkeys, MG causes swelling of the infraorbital sinuses. MS infection presents with lameness, swollen joints (hock and wing joints), and sternal bursitis [8, 19]. Systemic signs include decreased feed intake, reduced growth rates, and a drop in egg production [20, 10]. Chronic infections may result in airsacculitis, which leads to increased condemnation rates at slaughter [18, 21].

3.2. Fecal Abnormalities in Mycoplasma-Infected Poultry

While respiratory and joint signs are the predominant clinical features of avian mycoplasmosis, gastrointestinal manifestations are also observed, particularly in cases of severe systemic infection or co-infection with enteric pathogens. The classic clinical sign associated with MG and MS infection in chicken droppings is the presence of greenish or yellowish-green diarrhea. This fecal discoloration results from the excretion of biliverdin, a green bile pigment, secondary to anorexia and cholestasis induced by systemic inflammation [9]. As infected birds reduce feed intake due to malaise, respiratory distress, or lameness, bile pigment metabolism is altered, leading to green-tinged feces.

In cases of MS-induced synovitis, the pain and reluctance to move can lead to dehydration and reduced water consumption, resulting in the production of pasty, urate-rich droppings with a chalky white appearance due to increased uric acid concentration. The diarrhea associated with mycoplasmosis is typically not hemorrhagic; the presence of frank blood in the feces is more indicative of coccidiosis (e.g., Eimeria tenella, E. necatrix) or necrotic enteritis (Clostridium perfringens), which may occur as co-infections [2, 3].

Loose, watery droppings (diarrhea) can occur due to enteric involvement or as a non-specific sign of fever and systemic illness. However, primary mycoplasma-induced enteritis is uncommon; gastrointestinal signs are typically secondary to systemic disease or co-infection with other pathogens. For example, co-infection with Cryptosporidium baileyi has been shown to enhance MS colonization in chickens, potentially aggravating intestinal pathology and leading to malabsorptive diarrhea [7]. Furthermore, the stress induced by chronic mycoplasma infection can disrupt the gut microbiome, leading to dysbiosis and loose droppings [22].

3.3. Differential Diagnosis of Fecal Abnormalities

The clinical sign of green diarrhea in poultry warrants a broad differential diagnosis, including highly pathogenic avian influenza (HPAI), Newcastle disease, fowl cholera, and salmonellosis. The presence of joint swelling and respiratory signs, along with a history of slow spread within a flock, helps differentiate mycoplasmosis from acute viral infections. Metabolomics studies have identified potential biomarkers, including altered bile acid profiles, in the plasma of MS-infected hens that correlate with systemic metabolic derangements [23, 9].

Table 1: Differential Diagnosis of Fecal Abnormalities in Poultry

4. Diagnostic Approaches

4.1. Traditional Diagnostic Methods

A definitive diagnosis of avian mycoplasmosis relies on isolation of the organism in specialized media [24]. However, mycoplasmas are fastidious, slow-growing organisms that require extended incubation periods, making culture impractical for rapid diagnosis [4, 24]. Serological tests, including the rapid serum agglutination (RSA) test and enzyme-linked immunosorbent assay (ELISA), are widely used for flock-level screening [25, 26]. Commercial ELISA kits designed to detect antibodies against MG and MS are available, although cross-reactivity between species and variability in antibody responses necessitate confirmatory testing [27, 26].

4.2. Molecular Diagnostics

Polymerase chain reaction (PCR)-based methods have become the gold standard for the rapid and specific detection of avian mycoplasmas [28, 29, 30]. Conventional, multiplex, and real-time quantitative PCR (qPCR) assays targeting species-specific genes, such as the mgc2 gene for MG and the vlhA gene for MS, offer high sensitivity and specificity [28, 31, 30]. A duplex qPCR assay for MG can distinguish between wild-type and vaccine strains (e.g., ts-11), enabling effective surveillance of vaccination programs [28, 29].

Droplet digital PCR (ddPCR) provides absolute quantification of target DNA without the need for standard curves, and has been developed for detecting MG in duck flocks [32]. TaqMan-MGB probe-based real-time PCR assays have been designed to differentiate the MS-H vaccine strain from wild-type MS strains by targeting specific single nucleotide polymorphisms (SNPs) [33, 34, 35].

4.3. Advanced and Point-of-Care Technologies

Isothermal amplification methods, such as loop-mediated isothermal amplification (LAMP) and recombinase-aided amplification (RAA), enable field-deployable and point-of-care detection [36, 37, 38]. Colorimetric LAMP assays coupled with rapid DNA extraction methods allow for visual detection of MG without specialized equipment, making them suitable for resource-limited settings [36, 37]. The combination of RAA with CRISPR/Cas12a systems provides highly specific and sensitive detection platforms for both MG and MS [38, 39]. A gold nanoparticle-based lateral flow immunoassay has been developed for the simultaneous detection of three avian mycoplasmas, offering a user-friendly, rapid screening tool [40].

High-throughput sequencing and genomic analysis provide valuable insights into pathogen diversity, antimicrobial resistance determinants, and evolutionary dynamics [12, 41, 42, 43].

Figure 1: Diagnostic Workflow for Avian Mycoplasmosis

graph TD
    A["Clinical Signs: Respiratory, Joint, Fecal"] --> B{Flock-Level Screening}
    B --> C["Serology: RSA, ELISA"]
    C --> D{Positive Result?}
    D -- Yes --> E[Molecular Confirmation]
    D -- No --> F[Rule Out Other Pathogens]
    E --> G[DNA Extraction from Swabs/Tissues]
    G --> H[Species-Specific PCR/qPCR]
    H --> I{Specific Detection}
    I -- MG --> J["Strain Differentiation (Wild-type vs. Vaccine")]
    I -- MS --> K["Strain Differentiation (MS-H vs. Field")]
    I -- Negative --> L[Consider Culture or Sequencing]
    J --> M[Antimicrobial Susceptibility Testing]
    K --> M
    M --> N[Integrated Control Strategy]
    F --> O["Test for Co-infections: AIV, NDV, Bacteria, Parasites"]
    O --> E

5. Control Strategies

5.1. Biosecurity and Management

The cornerstone of mycoplasma control is the establishment of mycoplasma-free breeding flocks through rigorous biosecurity measures [3]. This includes the procurement of eggs and chicks from certified mycoplasma-free sources, strict all-in/all-out production systems, isolation of different age groups, and control of human and fomite movement [3, 44]. Hatchery contamination is a critical risk factor, and stringent disinfection protocols are essential for preventing vertical transmission [11]. Reducing stocking density, improving ventilation, and minimizing environmental stress are important for reducing the severity of clinical disease [10, 3].

5.2. Vaccination

Vaccination is a widely used strategy to control mycoplasmosis in commercial layers and breeders [6]. Both live-attenuated and inactivated vaccines are available for MG and MS [20, 19]. Live vaccines, such as the F-strain and ts-11 strain for MG, and the MS-H strain for MS, confer partial protection by reducing clinical signs and transmission [20, 45, 46, 34]. Recombinant vector vaccines, including those based on fowl poxvirus, fowl adenovirus, and Salmonella, are under development to provide safer and more efficacious alternatives [20, 47, 48, 49]. Subunit and inactivated vaccines targeting specific immunogenic proteins, such as MSPA, P50, Pdhβ-PdhD, and LP53, have shown promise in experimental trials [50, 25, 51, 26, 52, 53]. The combination of inactivated and subunit vaccines may enhance protective efficacy [51]. Protective mechanisms of MS vaccines involve long-lasting plasma cell responses and antibody-mediated immunity [54].

5.3. Antimicrobial Therapy and Resistance

Treatment of avian mycoplasmosis relies on antimicrobial agents that target protein synthesis, such as macrolides (e.g., tylosin, tilmicosin), tetracyclines (e.g., doxycycline, oxytetracycline), pleuromutilins (e.g., tiamulin, valnemulin), and fluoroquinolones (e.g., enrofloxacin) [55, 56, 5]. However, the emergence and spread of antimicrobial resistance (AMR) in mycoplasmas is a growing concern [4, 57, 43, 5]. Resistance to macrolides and fluoroquinolones has been reported in both MG and MS, often associated with mutations in target genes such as 23S rRNA and DNA gyrase [12, 58, 57, 59]. Efflux pump mechanisms have also been identified in M. iowae [12]. Pharmacokinetic/pharmacodynamic (PK/PD) modeling approaches are being used to optimize dosing regimens for novel pleuromutilin derivatives [55, 56]. The routine application of antimicrobial susceptibility testing (AST) is recommended to guide therapy and mitigate further resistance development [4, 24, 59, 60].

5.4. Alternative Control Approaches

Phytogenic compounds and herbal extracts are being investigated as alternatives to conventional antibiotics [61, 62, 14, 22, 63]. Berberine has been shown to inhibit MS infection by suppressing inflammatory and apoptotic responses in avian macrophages [17]. Luteolin and chrysosplenol D target the TatD nuclease of MG, disrupting its infectivity [14, 64]. Scutellaria baicalensis extracellular vesicles attenuate MG-induced inflammation through inhibition of TRPC1-STIM1/ORAI1 calcium channels [62]. Microemulsion formulations of essential oils have demonstrated synergistic effects against multi-resistant MG [65]. Probiotics, such as Bacillus coagulans, have been investigated for their ability to improve resistance to MS infection when sprayed during incubation [66].

5.5. Eradication and Surveillance

Eradication of MG and MS from breeder flocks is achievable through a combination of rigorous testing, culling of positive birds, and stringent biosecurity. National surveillance programs that involve molecular typing (e.g., MLST, vlhA genotyping) provide vital information on the genetic diversity and spread of field strains [41, 42, 31, 67]. The prevalence of mycoplasmas in wild bird populations, including house finches and free-ranging turkeys, serves as a reservoir for potential spillback into domestic poultry [68, 69, 67].

6. Conclusion

Avian mycoplasmosis remains a persistent challenge for the global poultry industry. The clinical signs, including greenish diarrhea, are not pathognomonic but serve as important indicators of systemic disease when combined with respiratory and joint pathology. The development of rapid, field-deployable molecular diagnostic assays has revolutionized the ability to detect and differentiate mycoplasma species, including vaccine and field strains [40, 36, 37, 38, 32]. Effective control requires an integrated approach encompassing strict biosecurity, strategic vaccination, prudent antimicrobial use guided by susceptibility testing, and ongoing surveillance of pathogen emergence and antimicrobial resistance [6, 4, 3]. The continued exploration of alternative therapeutic agents and novel vaccine platforms holds promise for more sustainable control strategies in the face of evolving antimicrobial resistance [66, 48, 22, 65, 52].

References

[1] Yacoub E, Baby V, Sirand-Pugnet P et al. A sweeping view of avian mycoplasmas biology drawn from comparative genomic analyses. BMC Genomics. 2025. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[2] Rodrigo CH, Kulappu Arachchige SN, Bushell RN et al. Complex pathogen interactions in upper respiratory tract infections in commercial free-range layers: A cross-sectional study. Vet Microbiol. 2026.

[3] Liu H, Pan S, Wang C et al. Review of respiratory syndromes in poultry: pathogens, prevention, and control measures. Vet Res. 2025.

[4] Sulyok KM, Kreizinger Z, Földi D et al. Molecular detection of antimicrobial resistance in livestock mycoplasmas: current status and future prospects. Front Vet Sci. 2025.

[5] Kamal MA, Salem HM, Alhotan RA et al. Unraveling Antimicrobial Resistance Dynamics in Mycoplasma gallisepticum: Insights Into Antibiotic and Disinfectant Interactions. Vet Med Sci. 2025.

[6] Chen J, Liu P, Chen Y. Pathogenic mechanisms and vaccine development for Mycoplasma gallisepticum in chickens. Front Microbiol. 2025.

[7] Zhang Y, Li Y, Wang Z et al. Cryptosporidium baileyi and Mycoplasma synoviae co-infection enhances M. synoviae colonization and aggravates tissue damage in chickens. Front Microbiol. 2026.

[8] Zhao H, Liu Y, Wei J et al. Identification and pathogenic analysis of Mycoplasma synoviae isolated from a broiler farm in China. Poult Sci. 2025.

[9] Wang C, Wang Q, Li Y et al. Plasma metabolomics of Mycoplasma synoviae infection in SPF White Leghorn hens by liquid chromatography-tandem mass spectrometry. Vet Res. 2025.

[10] Sudnick MC, Sauer EL, DuRant SE. Prior Infection Induces Long-Lasting Partial Immunity to Reduce Transmission within Flocks in an Avian Host-Pathogen System. Ecol Evol Physiol. 2025.

[11] Fang H, Zhang C, Li Q et al. Hatcheries' contamination: the molecular characterization and pathogenicity of Mycoplasma gallisepticum isolates in China. Poult Sci. 2025.

[12] Buni D, Kovács ÁB, Wehmann E et al. Identification and detection of genetic markers associated with antimicrobial susceptibility and evaluation of efflux pump mechanisms in Mycoplasma iowae. PLoS One. 2026.

[13] Guo Y, Hu W, Hu J et al. The intricate ballet of inflammation and autophagy: Insights from Mycoplasma gallisepticum-infected HD11 cells. Cytokine. 2025.

[14] Liu W, Wang S, Hu J et al. Targeting TatD nuclease and the MAPK Pathway: Luteolin multifaceted approach against Mycoplasma gallisepticum infection. Poult Sci. 2026.

[15] Zare S, Marenda MS, Arachchige SNK et al. Glyceraldehyde-3-phosphate dehydrogenase facilitates Mycoplasma synoviae colonisation in the lower respiratory system. Vet Microbiol. 2025.

[16] Zare S, Marenda MS, Klose SM et al. Enzymatic divergence of GAPDH in Mycoplasma synoviae: Comparative insights from MS-H and TS4 strains. Vet Microbiol. 2025.

[17] Sun Y, Hu W, Li S et al. Berberine inhibits Mycoplasma synoviae infection by suppressing PIK3CA-dependent inflammatory and apoptotic responses in avian macrophages. Microb Pathog. 2025.

[18] Gornatti-Churria CD, Jerry C, Ramsubeik S et al. High mortality in a commercial turkey flock associated with coinfection by Pasteurella multocida and Mycoplasmoides (Mycoplasma) gallisepticum. J Vet Diagn Invest. 2026.

[19] Wang Z, Chen L, Song L et al. Isolation and identification of Mycoplasma synoviae in Hebei, China, and evaluation of the immune protection efficacy of inactivated vaccines. Poult Sci. 2025.

[20] Hashish A, Chaves M, Osemeke O et al. Evaluation of Vaccination Programs in Layer Pullets Using Recombinant Fowl-Pox Mycoplasma gallisepticum Vaccine in Comparison to Commercially Available F-Strain Live Vaccines. Avian Dis. 2026.

[21] Mirzazadeh A, Liebhart D, Mitsch P et al. Recurring Airsacculitis in Late-Stage Production Leading to High Slaughterhouse Condemnation in a Commercial Turkey Farm. Avian Dis. 2025.

[22] Kan Q, Luo J, Zhao L et al. Tengchuan compound mixture ameliorates Mycoplasma Synoviae-induced synovitis: An integrated network pharmacology, metabolomics, and 16S rRNA sequencing study. Poult Sci. 2025.

[23] Wei X, Sun M, Zhang K et al. Potential Biomarkers and Underlying Pathogenesis of Mycoplasma synoviae Infection: Insights from Metabolomics Analysis. Microorganisms. 2025.

[24] Taiyari H, Abu J, Zakaria Z et al. Different media affect the growth and antimicrobial minimum inhibitory concentrations of Mycoplasma gallisepticum and Mycoplasma synoviae. J Microbiol Methods. 2026.

[25] Li H, Hu Z, Wang G et al. Development of an indirect ELISA based on a new specific lipoprotein LP53 for the detection of antibodies against Mycoplasma synoviae. BMC Vet Res. 2025.

[26] Liu Y, You G, Shi J et al. Indirect ELISA developed to detect antibodies against Mycoplasma synoviae P50 protein via immunoproteomic screening. Appl Microbiol Biotechnol. 2025.

[27] Omotainse OS, Noormohammadi AH, Jeffery N et al. Differential systemic antibody responses to Mycoplasma synoviae MSPA variants after vaccination and/ or field challenge. Vet Microbiol. 2025.

[28] Fan P, Liu Z, Xu Y et al. Strain-specific detection of Mycoplasma gallisepticum: A duplex qPCR assay for vaccine efficacy and infection surveillance. Poult Sci. 2026.

[29] Xin J, Zhang J, Liang S et al. A multiplex TaqMan real-time PCR assay for differential identification of wild-type and vaccine strains of Mycoplasma gallisepticum. Poult Sci. 2026.

[30] Xu B, Wang S, Yao W et al. New molecular diagnostic targets for Avibacterium paragallinarum and a set of single-plex and multiplex qPCR methods for the rapid differential diagnosis of Mycoplasma gallisepticum, Mycoplasma synoviae, and Avibacterium paragallinarum. Poult Sci. 2025.

[31] Zhang W, Deng L, Liu T et al. Research note: Prevalence and vlhA gene genotyping analysis of Mycoplasma synoviae in poultry from 2021 to 2023 in central China. Poult Sci. 2025.

[32] Zhou L, Wang A, Song F et al. Development of droplet digital PCR (ddPCR) for the detection and quantification of Mycoplasma gallisepticum in duck flocks. Microb Pathog. 2025.

[33] Chen M, Guo M, Zhang C et al. Enhancing Mycoplasma synoviae control: A novel quantitative real-time PCR approach to differentiate MS-H vaccine strain and field strains. Poult Sci. 2025.

[34] Liu Z, Zhou S, Meng C et al. A TaqMan-MGB real-time PCR for discriminating between MS-H-live vaccine and field Mycoplasma synoviae strains. Microbiol Spectr. 2025.

[35] Zhao L, Tang X, Guo W et al. Using a novel gene site to develop a duplex real-time TaqMan MGB probe PCR method for the SNP detection and differentiation between the MS-H live vaccine strain and wild-type Mycoplasma synoviae strains. Poult Sci. 2025.

[36] Jing W, Cai Q, Liang Y et al. High-throughput colorimetric LAMP detection of Mycoplasma gallisepticum with intelligent algorithm-assisted analysis. Anal Methods. 2026.

[37] Mayne R, Pant SD, Huang J et al. A field-ready colourimetric LAMP assay for detection of Mycoplasma gallisepticum using rapid DNA extraction. Res Vet Sci. 2026.

[38] Hu Q, Zhang R, Liu J et al. A rapid and field-deployable RAA-CRISPR/Cas12a platform for detection of Mycoplasma gallisepticum in poultry. BMC Vet Res. 2026.

[39] Hu Q, Liu J, Zhang W et al. Rapid nucleic acid detection of Mycoplasma synoviae using dual-mode RAA-CRISPR/Cas12a system. Poult Sci. 2026.

[40] Zidi S, Yacoub E, Chniba I et al. Development and validation of a rapid triple-target gold nanoparticle lateral flow immunoassay for detection of three avian mycoplasmas immunochromatographic strip test for avian mycoplasma detection. BMC Microbiol. 2026.

[41] Stefani E, Morales-Arce AY, Nai G et al. Molecular typing of Mycoplasma synoviae in industrial and backyard poultry: a 14-year study in Italy. Appl Environ Microbiol. 2026.

[42] Tu L, Li X, Liu Y et al. Genetic Diversity and Emerging Trends of Mycoplasma synoviae in China: Insights from a 2024 Nationwide MLST Study. Microorganisms. 2026.

[43] Kachabi K, Pourbakhsh SA, Zahraei Salehi T. Comparative Genomic Analysis of Six Mycoplasma Gallisepticum Strains: Insights into Genetic Diversity and Antibiotic Resistance. Arch Razi Inst. 2025.

[44] Tipu JH, Miah R, Islam O et al. Molecular and Seroprevalence of Mycoplasma gallisepticum in Turkeys in Sylhet District of Bangladesh. Vet Med Sci. 2025.

[45] Kamathewatta KI, Kanci Condello A, Ekanayake D et al. Day-old vaccination with the Vaxsafe MG304 live-attenuated vaccine protects chickens from tracheal transcriptional changes induced by chronic infection with Mycoplasma gallisepticum. Vaccine. 2025.

[46] Liu CC, Suzuki C, Sato K et al. A newly developed temperature-sensitive Mycoplasma synoviae live attenuated strain prevents pathological lesions of the respiratory and reproductive tracts in chickens caused by a wild-type M. synoviae strain. J Vet Med Sci. 2025.

[47] Liu Y, Li W, Li G et al. Protection of chickens against M. synoviae infection by vaccination with a recombinant fowl adenovirus 4-P50. Microb Pathog. 2026.

[48] Sabir R, Liu M, Saeed HA et al. Next-generation live vector vaccine targeting Mycoplasma synoviae and Mycoplasma gallisepticum via recombinant Salmonella. Vaccine. 2026.

[49] Zhang G, Han L, Zhao Y et al. Construction and protective evaluation of a recombinant attenuated Salmonella vaccine delivering Mycoplasma synoviae antigens. Virulence. 2025.

[50] Zhao L, Guo W, Zhang B et al. Identification and efficacy assessment of novel immunoprotective antigens from Mycoplasma synoviae for vaccine development. NPJ Vaccines. 2025.

[51] Yi C, Xu Q, Han Y et al. The combination of inactivated and subunit vaccines enhances protective efficacy against Mycoplasma synoviae. Poult Sci. 2025.

[52] Ying-Fen L, Chun S, Jun Y et al. Recombinant adenovirus expressing pdhβ-pdhD fusion protein produces robust immune responses and partial protection against Mycoplasma Synoviae challenge in chickens. Poult Sci. 2025.

[53] Yang P, Li Y, Zhou N et al. Evaluating the MS-HLJ strain as a novel inactivated vaccine candidate: Long-term immune protection against Mycoplasma synoviae in poultry. Microb Pathog. 2025.

[54] Kamathewatta KI, Kanci Condello A, Shil PK et al. Mechanisms of vaccine protection in chickens against challenge with virulent Mycoplasma synoviae. Vet Res. 2025.

[55] Yang W, Ding H, Ma X et al. Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum. Poult Sci. 2026.

[56] Xia X, Zhao H, Li Y et al. Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens. Poult Sci. 2025.

[57] Forero-Marin S, Gomez AP, Beltran-Leon M et al. A first look into the genomic characterization and fluoroquinolone resistance genotypes of Mycoplasma spp. in Colombian poultry. Poult Sci. 2026.

[58] Kovács ÁB, Wehmann E, Bekő K et al. Genome-wide association study of Mycoplasma anserisalpingitidis strains for antibiotic susceptibility. Sci Rep. 2026.

[59] Rufai AA, Zakaria Z, Yu CY et al. Prevalence and antimicrobial susceptibility of Mycoplasma gallisepticum and Mycoplasma synoviae isolated from the central peninsular Malaysia. Poult Sci. 2025.

[60] Li Y, Liang J, Li W et al. The analysis of antimicrobials epidemiological cut-off values of mycoplasma gallisepticum isolated from goose. Poult Sci. 2025.

[61] Yan Y, Liao L, Fan Y et al. Evaluation and Analysis of the Efficacy of Four Chinese Herbal Medicines and Formulations in Preventing and Treating Mycoplasma gallisepticum Infection in Chickens. Vet J. 2026.

[62] Xu F, Bao L, Yao Y et al. Mechanism of Scutellaria baicalensis extracellular vesicles in attenuating Mycoplasma gallisepticum-induced inflammation via TRPC1 - STIM1/ORAI1 channel inhibition. Poult Sci. 2026.

[63] Wan Z, Liu T, Cheng A et al. Arbutin improves lung injury in chicks induced by Mycoplasma gallisepticum infection. Poult Sci. 2025.

[64] Wang S, Niu D, Hu J et al. Exploiting an evolutionary constraint: Targeting TatD nuclease with chrysosplenol D disrupts Mycoplasma gallisepticum infection. Int J Biol Macromol. 2025.

[65] Hosny RA, Masry DMAE, Saad ASA et al. Highlight on the synergistic effect of different microemulsion formulations on the virulence determinants of multi-resistant Mycoplasma gallisepticum recovered from poultry. Int Microbiol. 2025.

[66] Wei Y, Zhao X, Chen X et al. Effect of spraying Bacillus coagulans during incubation on hatchability, chick growth, resistance to Mycoplasma synoviae, and cecal microbiota. Poult Sci. 2026.

[67] Reinoso-Pérez MT, Díaz Ávila LE, García Jacobo S et al. Emerging genetic diversity of Mycoplasma gallisepticum in Mexican house finches: Evidence of possible independent spillover events. Infect Genet Evol. 2025.

[68] Edge AC, Moorman CE, Pacifici K et al. Regional Pathogen Surveillance of Free-Ranging Wild Turkeys (Meleagris gallopavo) in North Carolina, USA. J Wildl Dis. 2026.

[69] Dhondt AA, Dobson AP, Dhondt KV et al. Alternate Evolutionary Trajectories Following a Pathogen Spillover into a Novel Host: The Case of Mycoplasma gallisepticum in House Finches (Haemorhous mexicanus). J Wildl Dis. 2025.

[70] Marín-Villa J, Alzate-Vargas JF, Ramírez TG et al. Serological evidence and risk factors of Mycoplasma gallisepticum and Mycoplasma synoviae exposure in trafficked parrots and macaws in Colombia. Open Vet J. 2025.

[71] Kulappu Arachchige SN, Abeykoon AMH, Stevenson MA et al. Assessment of tracheal mucosal thicknesses is a preferable method for evaluation of the immunogenicity of Mycoplasma gallisepticum vaccines in poultry. Vaccine. 2026.

[72] Wang Y, Li S, Guo Q et al. Enhancer of Zeste homolog 2-mediated histone H3 lysine 27 trimethylation silences LIM domain-containing protein 1 and activates hippo signaling in Mycoplasma pathogenesis. Int J Biol Macromol. 2025.

[73] Lu Z, Liu X, Zhang Y et al. Oral immunization with recombinant Saccharomyces cerevisiae expressing TM1 of Mycoplasma gallisepticum induces unique specific antibodies and protective immunity. Microb Pathog. 2025.

[74] Vastel M, Gaurivaud P, Tardy F et al. Standardized analysis of nuclease activities in Mycoplasma species colonizing swine, poultry, and small ruminants. FEMS Microbiol Lett. 2025.

[75] Zhong L, Wu C, Liao L et al. Comparative omics analysis of the impact of Mycoplasma synoviae infection on the immune mechanisms of poultry spleen. Virulence. 2025.

[76] Ezzat AM, Youssef AO, Abou-Omar MN et al. Development of Tb-Anthracene-9-Carboxaldehyde complex as a novel optical biosensor for rapid mycoplasma detection in serum samples of infected chickens. Spectrochim Acta A Mol Biomol Spectrosc. 2025.

[77] Zhao Y, Su D, Li M et al. Application of Pyrococcus furiosus Argonaute coupled with RPA for highly sensitive and specific detection of Mycoplasma gallisepticum. Poult Sci. 2025.

[78] Zhou L, Chen X, Song F et al. Molecular epidemiological investigation and identification of Mycoplasma gallisepticum in large-scale duck farms. Microb Pathog. 2025.

[79] Guo M, Zhao X, Zhao X et al. Genomic and transcriptomic analyses reveal the genetic basis of leg diseases in laying hens. Poult Sci. 2025.

[80] Li S, Zou M, Wang Y et al. Matrix metalloproteinase 7 (MMP7) as a molecular target for Mycoplasma gallisepticum (MG) resistance in chickens. Int J Biol Macromol. 2025.

[81] Zhang N, Jia Y, Li W et al. Epidemiological and molecular characterization of investigation of Mycoplasma gallisepticum of goose origin in Guangdong (China). Poult Sci. 2025.